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A 56-year-old male current smoker with a 77 pack-year history underwent left upper lobectomy in June 2010 
followed by adjuvant chemotherapy with cisplatin and gem-
citabine for pathological stage IIIA non–small-cell lung can-
cer (NSCLC). He was administered chemotherapy, including 
carboplatin, pemetrexed, and bevacizumab, starting in April 
2011 due to recurrence of the NSCLC in the supraclavicular 
lymph node (LN). In July 2012, a computed tomography scan 
detected recurrence of the NSCLC in the axillary LNs. The 
patient was treated with erlotinib because an active mutation 
of the epidermal growth factor receptor (EGFR) was detected 
in the primary lesion using the reverse transcription poly-
merase chain reaction (RT-PCR)-invader method. However, 
the erlotinib therapy achieved a stable disease status for only 
8 weeks, regardless of the presence of a deletion in exon 19 
of EGFR  (E746-A750del type 2).
The patient was referred to our institution in November 
2012 due to regrowth of the supraclavicular and axillary 
LN metastasis. As a result of a poor response to erlotinib, 
we performed a repeat biopsy of the metastatic supracla-
vicular LN with the aim of identifying another driver muta-
tion, such as that involving the following: the echinoderm 
 microtubule-associated protein-like 4 gene, the anaplastic 
lymphoma kinase (EML4-ALK) gene, the kinesin family 
member 5B gene, the rearranged during transfection (KIF5/
RET) fusion gene, c-ros oncogene 1 (ROS1), and an EGFR 
resistance gene (e.g., T790M).
The supraclavicular LN was assumed to contain a 
metastatic lesion from the resected primary lung adeno-
carcinoma of a papillary subtype, as confirmed using 
 hematoxylin-eosin staining and immunohistochemistry 
(Figure 1). The primary lesion and metastatic LN were sep-
arately examined for mutations of the EGFR gene and the 
KIF5/RET fusion gene using RT-PCR and a direct sequenc-
ing method.1,2 A deletion in exon 19 of EGFR was detected 
in the primary lesion only, while the wild type of EGFR was 
detected in the metastatic LN and T790M was detected in 
neither the primary nor metastatic lesions. In addition, both 
the primary lesion and metastatic LN harbored the KIF5/
RET fusion gene (Figures 2 and 3).
Although there have thus far been few reports of 
patients with both an EGFR mutation and the EML4-ALK 
fusion gene,3 oncogenic driver mutations are usually mutu-
ally exclusive. The KIF5/RET fusion gene is a previously 
unidentified lung adenocarcinoma driver mutation found 
in 0.9–1.7% of NSCLC cases.1,2,4 Importantly, lung adeno-
carcinoma patients with the KIF5/RET fusion gene can be 
successfully treated with RET inhibitors, such as vandetanib 
and cabozantinib.5
Despite the presence of active EGFR mutations in 
the primary lesion, the patient exhibited a poor response, 
with metastatic LNs. Therefore, there is a possibility that 
only adenocarcinoma cells with the KIF5B-RET fusion 
gene metastasized. To the best of our knowledge, this is the 
first case in which lung adenocarcinoma has been identi-
fied to harbor both an EGFR mutation and the KIF5B-RET 
fusion gene. When genetic information and the response to 
molecular targeted therapy are not correlated, oncologists 
should be aware of the possibility of other oncogenic driver 
mutations.
In conclusion, this case might illustrate the need for 
multiple rather than sequential testing in the future, challenge 
the theory of mutually exclusive driver alterations, and sug-
gest a new molecular mechanism of resistance against EGFR 
tyrosine kinase inhibition.
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FIGURE 1.  Histology of (A) the primary tumor and (B) metastatic supraclavicular LN. (1) The adenocarcinoma component 
with a predominant papillary structure (hematoxylin and eosin, ×200). An immunohistochemical examination revealed that the 
primary lesion and metastatic lesion were both positive for (2) thyroid transcription factor 1 (TTF1)/Napsin A and (3) CK7 and 
negative for (4) monoclonal anti-anaplastic lymphoma kinase (ALK) antibodies (5A4, ×200). LN, lymph node.
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FIGURE 2.  Results of fusion-specific 
reverse transcription polymerase chain 
reaction of the primary lesion and met-
astatic lymph node. KIF5B-RET fusion 
gene, predicted product size of 154 bp; 
(lane 1) no template control, (lane 2) 
primary lesion, (lane 3) metastatic LN, 
(lane 4) negative control, and (lane 
5) positive control. Primers for detec-
tion of KIF5B (exon 15)-RET (exon 12) 
fusion genes: forward (KIF5B exon 15) 
5′-CTTAAGGAAATGACCAACCACC-3′; 
and reverse (RET exon 12) 
5′-TCCAAATTCGCCTTCTCCTAGAG-3′.
KIF5B exon15 RETexon12
KIF5B exon15 RETexon12
Metastatic LN
Primary lesion
A
B
FIGURE 3.  Gene sequence analysis 
of (A) the primary tumor and (B) 
metastatic supraclavicular lymph 
node. A direct sequence analysis 
revealed a variant 1 mutation of the 
KIF5B-RET fusion gene in the meta-
static lesion.
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